|
KMID : 1101420180500010020
|
|
Korean Journal of Clinical Laboratory Science
2018 Volume.50 No. 1 p.20 ~ p.28
|
|
|
Performance Evaluation of In Vitro Diagnostic Reagents for Mycobacterium tuberculosis and Non-tuberculous Mycobacteria by FDA Approval
|
|
Kim Yeun
Park Sun-Young
Kim Jung-Ho
Chang Yun-Hee
Ha Sun-Mok
Choi Yeon-Im
Lee Hye-Young
|
|
|
Abstract
|
|
|
|
Tuberculosis (TB) is a bacterial infection disease caused by members of the species Mycobacterium tuberculosis (MTB) complex. Approximately one third of the world's population is infected with TB. In Korea, approximately 40,000 new patients are identified each year. Moreover, infections from non-tuberculous mycobacteria (NTM) have also increased. In the diagnosis of TB and NTM, traditional bacterial cultures are required for 3 to 4 weeks. Therefore, rapid and accurate diagnostic tests for TB and NTM are needed. To distinguish between TB and NTM, a range of diagnostic methods have been developed worldwide. In vitro diagnostic assays are constantly being developed to meet the increasing need for the rapid and accurate identification for TB and NTM. On the other hand, the performance evaluations of in vitro diagnostic reagents for TB and NTM are lacking. Recently, the Korea Food and Drug Administration (KFDA) issued a guideline for in vitro diagnostic reagents for MTB and NTM. Here, this study analyzed the performance of currently developed in vitro diagnostic reagents for TB and NTM in the US FDA. This analysis of US FDA approved molecular assays could serve as a useful reference for an evaluation of the reagent performance of TB and NTM.
|
|
|
KEYWORD
|
|
|
Tuberculosis, Sensitivity, Specificity, Diagnostic test approval, Food and drug administration
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|